Drugs for SARS-COV 2 Flashcards
1
Q
What do we use to treat SARS-COV2?
A
• Antibodies as they are specific
2
Q
How can we block virus ENTRY?
A
- Use monoclonal antibodies
- ACE2 inhibitor – has to be specific to SPIKE protein on virus
- Peptides – can target the virus - still in development
3
Q
What is RBD?
A
- Receptor binding domain – known as the S1 region
* ACE inhibitor has to prevent interaction between SPIKE RBD and ACE 2 – limits cell entry by doing so
4
Q
Where can we get these antibodies from?
A
• Vaccines/convalescent plasma
5
Q
What is convalescent plasma
A
• Liquid part of blood taken from people who have recovered from an illness to help OTHERS recover
6
Q
What is plasma
A
- Clear liquid fluid part of the blood which carries red blood cells
- Proteins which form blood clots are in the plasma
7
Q
antibodies CLINIAL TRIALS
Recovery trial
A
• Randomised controlled open cohort adaptive trial – NO significant clinical benefit
8
Q
antibodies CLINIAL TRIALS
Remap- cap
A
- International, randomised embedded multifactorial adaptive trial – NO significant clinical benefit
- Decided NOT to use convalescent plasma
9
Q
what do Monoclonal antibodies do
A
• Neutralises virus
10
Q
How are Monoclonal antibodies derived
A
- Derived from clone of a single B-cell and is produced in large quantities
- Due to it being a protein it can be manufactured easily
11
Q
3 anti-SARS-COV2 mAB treatment
A
- 3 types have been given emergency use authorisation for treatment of mild to moderate COVID-19
- BAMLANIVIMAB
- CASIRIVIMAB used when prophylaxis (treatment) doesn’t work
- SOTROVIMAB
- Neutralising mAB’s which bind to different overlapping epitopes of the SARS-COV2 spike protein RBD
- Epitope = part of an antigen molecule which antibody attaches to
